Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Early MRD-Negativity May Predict for Favorable Outcome Irrespective of Allotransplantation in TKI-Treated Patients with Ph-Positive Acute Lymphoblastic Leukemia

Helena Hohtari, MD, Marjatta Sinisalo, Tapio Nousiainen, MD PhD, Perttu Koskenvesa, MD, Ulla Wartiovaara-Kautto, MD PhD, Satu Mustjoki, MD PhD, Pirjo Koistinen, MD PhD, Marjaana Säily, MD PhD, Maija Itälä-Remes, Erkki Elonen, MD PhD, Kari Remes, MD PhD, Kimmo Porkka, MD PhD

Blood (2016) 128 (22): 1598.

https://doi.org/10.1182/blood.V128.22.1598.1598

Published: 2016

Journal Articles

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Arne Kolstad, MD PhD, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, MD, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, MD PhD, Niels S. Andersen, MD PhD, Peter de Nully Brown, MD PhD, Christian H Geisler

Blood (2016) 128 (22): 146.

https://doi.org/10.1182/blood.V128.22.146.146

Published: 2016

Journal Articles

Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group

Riikka Räty, Tuomo Honkanen, Esa Jantunen, MDPhD, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Outi Kuittinen, Minna Lehto, Maija Mikkola, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, MD, Sanna Siitonen, Merja Suominen, MD, Mirja Vapaatalo, Erkki Elonen

Blood (2014) 124 (21): 1749.

https://doi.org/10.1182/blood.V124.21.1749.1749

Published: 2014

Journal Articles

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Blood (2014) 123 (19): 2953–2959.

https://doi.org/10.1182/blood-2013-12-541953

Published: 2014

Journal Articles

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

Blood (2013) 122 (21): 482.

https://doi.org/10.1182/blood.V122.21.482.482

Published: 2013

Journal Articles

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Blood (2012) 120 (21): 747.

https://doi.org/10.1182/blood.V120.21.747.747

Published: 2012

Journal Articles

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Blood (2010) 115 (8): 1530–1533.

https://doi.org/10.1182/blood-2009-08-236570

Published: 2010

Includes: Supplemental data

Journal Articles

90 y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Blood (2009) 114 (22): 932.

https://doi.org/10.1182/blood.V114.22.932.932

Published: 2009

Journal Articles

Elderly Patients with Mantle Cell Lymphoma (MCL) – Efficacy and Feasibility of Prolonged Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and Followed by Rituximab Maintenance Treatment. A Prospective Study by the Finnish Lymphoma Group

Erkki Elonen, Riikka Räty, Tuomo Honkanen, Esa Jantunen, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, Outi Kuittinen, Minna Lehto, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, Sanna Siitonen, Merja Suominen, Mirja Vapaatalo

Blood (2008) 112 (11): 1001.

https://doi.org/10.1182/blood.V112.11.1001.1001

Published: 2008

Journal Articles

Acute Lymphoblastic Leukemia with “Normal” Karyotype is not without Genomic Aberrations.

Anu Usvasalo, Riikka Räty, Arja Harila-Saari, Pirjo Koistinen, Eeva-Riitta Savolainen, Kim Vettenranta, Sakari Knuutila, Erkki Elonen, Ulla M. Saarinen-Pihkala

Blood (2008) 112 (11): 1491.

https://doi.org/10.1182/blood.V112.11.1491.1491

Published: 2008

Journal Articles

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Blood (2008) 112 (7): 2687–2693.

https://doi.org/10.1182/blood-2008-03-147025

Published: 2008

Journal Articles

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Blood (2008) 112 (4): 1005–1012.

https://doi.org/10.1182/blood-2008-02-140665

Published: 2008

Includes: Supplemental data

Journal Articles

Successful Preemptive Treatment of Molecular Relapse after Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

Niels S. Andersen, MD, Lone B. Pedersen, Anna Laurell, MD, Erkki Elonen, MD, Arne Kolstad, MD, Christian H. Geisler, MD

Blood (2007) 110 (11): 1281.

https://doi.org/10.1182/blood.V110.11.1281.1281

Published: 2007

Journal Articles

STAT5 Signaling Is Associated with the Outcome of Follicular and Mantle Cell Lymphoma Patients Treated with Immunochemotherapy.

Sirpa Leppä, MD, PhD, Minna Taskinen, MSci, Antti Sommarhem, MD, Erkki Elonen, MD, PhD, Matti Nykter, PhD, Outi Monni, PhD, Tuomo Timonen, MD, PhD, Sampsa Hautaniemi, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Seppo Meri, MD, PhD

Blood (2007) 110 (11): 2626.

https://doi.org/10.1182/blood.V110.11.2626.2626

Published: 2007

Journal Articles

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Blood (2007) 110 (11): LB1.

https://doi.org/10.1182/blood.V110.11.LB1.lb1

Published: 2007

Journal Articles

Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Finland.

Anu Usvasalo, Ulla Saarinen-Pihkala, Erkki Elonen, Riikka Raty, Kim Vettenranta

Blood (2006) 108 (11): 1885.

https://doi.org/10.1182/blood.V108.11.1885.1885

Published: 2006

Journal Articles

Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

Christian H. Geisler, MD, PhD, Erkki Elonen, MD, Ph.D, Arne Kolstad, MD, Ph.D, Anna Laurell, MD, Ph.D, Lone B. Pedersen, B of Sc, Niels S. Andersen, MD, Ph.D, Mats Jerkeman, MD, Ph.D, Marie Nordstrom, MD, Ph.D, Grethe F. Lauritzen, MD, Ph.D, Elisabeth Ralfkiaer, MD, Ph.D, Maans Akerman, MD, Ph.D, Christer Sundstrom, MD, Ph.D, Ruth Langholm, MD, Ph.D, Marja-Liisa Karjalainen-Lindsberg, MD, Ph.D, Outti Kuittinen, MD, Ph.D, Mikael Eriksson, MD, Ph.D, Nordic Lymphoma Group

Blood (2005) 106 (11): 2429.

https://doi.org/10.1182/blood.V106.11.2429.2429

Published: 2005

Journal Articles

Nordic Mantle Cell Lymphoma (MCL) Project: Prolonged Follow-Up of 86 Patients Treated with BEAM/BEAC + PBSCT Confirms That Addition of High-Dose Ara-C and Rituximab to CHOP Induction + In-Vivo Purging with Rituximab Increases Clinical and Molecular Response Rates, PCR-Neg. Grafts, Failure-Free, Relapse-Free and Overall Survival.

Christian H. Geisler, MD, PhD, Erkki Elonen, MD, PhD, Arne Kolstad, MD, PhD, Anna Laurell, MD, PhD, Niels S. Andersen, MD, PhD, Lone B. Pedersen, Mats Jerkeman, MD, PhD, Marie Nordstroem, MD, PhD, Grete F. Lauritzen, MD, PhD, Elisabeth Ralfkiaer, MD, PhD, Maans Aakerman, MD, PhD, Christer Sundstroem, MD, PhD, Ruth Langholm, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD

Blood (2004) 104 (11): 8.

https://doi.org/10.1182/blood.V104.11.8.8

Published: 2004

Journal Articles

Novel DNA Copy Number Changes in Hematological Malignancies: A cDNA-Based CGH Microarray Screening of CML, AML and CLL Cases without Chromosomal Imbalances in G-Banding.

Tuija Lundan, M.Sc., Anne Oikarainen, M.Sc., Lena Hafren, M.Sc., Maija Wolf, Ph.D., Erkki Elonen, M.D., Juhani Vilpo, M.D., Kimmo Porkka, M.D., Sakari Knuutila, Ph.D.

Blood (2004) 104 (11): 4418.

https://doi.org/10.1182/blood.V104.11.4418.4418

Published: 2004

Journal Articles

Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study

Tapani Ruutu, Liisa Volin, Terttu Parkkali, Eeva Juvonen, Erkki Elonen

Blood (2000) 96 (7): 2391–2398.

https://doi.org/10.1182/blood.V96.7.2391

Published: 2000

NARROW

Early MRD-Negativity May Predict for Favorable Outcome Irrespective of Allotransplantation in TKI-Treated Patients with Ph-Positive Acute Lymphoblastic Leukemia

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

90 y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Elderly Patients with Mantle Cell Lymphoma (MCL) – Efficacy and Feasibility of Prolonged Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and Followed by Rituximab Maintenance Treatment. A Prospective Study by the Finnish Lymphoma Group

Acute Lymphoblastic Leukemia with “Normal” Karyotype is not without Genomic Aberrations.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Successful Preemptive Treatment of Molecular Relapse after Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

STAT5 Signaling Is Associated with the Outcome of Follicular and Mantle Cell Lymphoma Patients Treated with Immunochemotherapy.

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Finland.

Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

Novel DNA Copy Number Changes in Hematological Malignancies: A cDNA-Based CGH Microarray Screening of CML, AML and CLL Cases without Chromosomal Imbalances in G-Banding.

Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only